samedan logo
 
 
spacer
home > epc > winter 2008 > the finnish line
PUBLICATIONS
European Pharmaceutical Contractor

The Finnish Line

Establishing the rights to inventions can be a tricky business. Hanna Paloheimo of Borenius & Kemppinen negotiates Finland’s legislative take on diverse contractual relations

As the value of inventions is extremely high in the pharmaceutical sector, particularly close attention should be paid to the proper transfer of rights and diligent management of inventor relations. This article discusses Finnish legislation on employee inventions, the recent changes concerning university inventions and the management of inventions and inventor relations in outsourcing research in Finland.

EMPLOYEE INVENTIONS

Main Rule Regarding Inventions
The basic issue relating to inventions that originate within employment occurs when the company of employment desires the possession of the invention, either for its own use or for the purposes of transferring it to a contractual partner. In Finland, certain crucial pieces of mandatory legislation regulate this field. Employee inventions are regulated by the Act on the Right in Employee Inventions (656/1967, hereafter the Employee Inventions Act). More detailed provisions are set out in the Decree on the Right to Employee’s Inventions (527/1988). The main principle of invention ownership is provided by Section 3 of the Employee Inventions Act, which states that an employee shall have the same rights in his/her inventions as other inventors, unless otherwise provided by a piece of legislation. This means that, primarily, the employee owns all rights to an invention made by him or her; a specific procedure and assignment of these rights is required to render the invention the property of the employer.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hanna Paloheimo is an Attorney at Law and MSc. She advises on IP and contract lawrelated questions with particular emphasis on life sciences and IP litigation, as well as on regulatory affairs in the chemical, pharmaceutical and life science sectors. She received her Master of Law degree in 2000 and her Master of Science degree in 1998. In addition to this, she has also studied at Edinburgh University, Scotland, where she participated in an Honours graduate course in Immunology (1994-1995). Hanna’s experience prior to B&K includes working in the patent department and as a visiting in-house lawyer at a major Finnish pharmaceutical company, as well as work in a molecular biology research group at Helsinki University.
spacer
Hanna Paloheimo
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement